Side-by-side · Research reference

AHK-CuvsCagrilintide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BPhase 3HUMAN-REVIEWED35/64 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Cagrilintide

Long-Acting Amylin Analogue · Phase 3

7.5%Additional weight loss vs semaglutideAhmed 2026

Once weeklyDosing frequencyBailey 2026

Dual AMYR/CTRReceptor agonismBailey 2026

SQ · Once WeeklyBailey 2026

01Mechanism of Action

Parameter

AHK-Cu

Cagrilintide

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026 Yamauchi 2026

Feedback intact?

—

Yes — acts via physiological amylin pathways

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

Cagrilintide

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once weekly (subcutaneous)Bailey 2026

Long-acting formulation.

Route

Topical — scalp or dermal application

Subcutaneous injectionBailey 2026

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026 Ahmed 2026

Duration

Not established — cosmetic protocols typically 8–12 weeks

26–52 weeks in trialsYamauchi 2026

Standard dose (combination)

—

Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026

Phase 3 REDEFINE 5 trial dosing.

Monotherapy dosing

—

Dose-dependent, under investigation

Monotherapy trials reported in meta-analysis.

03Metabolic / Fat Loss Evidence

Parameter

AHK-Cu

Cagrilintide

Weight loss vs semaglutide

—

7.47% greater percentage weight lossAhmed 2026

CagriSema combination vs semaglutide monotherapy (meta-analysis).

Absolute weight change

—

Significantly greater absolute weight reductionAhmed 2026

Mean difference favoring combination therapy.

Mechanism

—

Central satiety inductionBailey 2026

BMI reduction

—

Significant BMI reduction vs comparatorAhmed 2026

Glycemic benefit

—

Reduced fasting glucose and HbA1cAhmed 2026

Synergistic effect with semaglutide in combination.

Lipid effects

—

Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglyceridesAhmed 2026

Body composition

—

Predominant fat loss with weight reduction

Mitochondrial function

—

In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026

C2C12 myotube study; clinical relevance under investigation.

Combination rationale

—

Multi-pathway approach: amylin (satiety) + GLP-1 (incretin)Lempesis 2026

Key publications

—

REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026 Ahmed 2026 Bailey 2026

04Side Effects & Safety

Parameter

AHK-Cu

Cagrilintide

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Gastrointestinal

—

Nausea, diarrhea (common with incretin-based therapies)Pardali 2026

Dietary management and nutritional monitoring recommended.

Injection site reactions

—

Local reactions possible with subcutaneous administration

Safety profile

—

Generally consistent with incretin-based therapies

Phase 3 and meta-analysis safety data.

Tolerability

—

Tolerability considerations similar to GLP-1RAs

Muscle preservation

—

Lean mass considerations during weight loss

In vitro mitochondrial effects observed; clinical impact under investigation.

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Cagrilintide

·Hypersensitivity to cagrilintide or formulation components

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Cagrilintide

·Severe gastrointestinal disease
·History of pancreatitis (incretin-based therapy consideration)

05Administration Protocol

Parameter

AHK-Cu

Cagrilintide

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026 Bailey 2026

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Cagrilintide

+ Semaglutide

Strong

View Semaglutide →

Cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.

CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Frequency: Once weekly subcutaneous
Duration: 26–52 weeks (trial data)
Primary benefit: Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation

Yamauchi 2026 Ahmed 2026 Bailey 2026